Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

76.98USD
22 May 2017
Change (% chg)

$-0.82 (-1.05%)
Prev Close
$77.80
Open
$77.90
Day's High
$77.92
Day's Low
$76.85
Volume
1,799,528
Avg. Vol
1,111,861
52-wk High
$86.71
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company
Thursday, 18 May 2017 06:07am EDT 

May 18 (Reuters) - United Therapeutics Corp :United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company.United therapeutics - amendment to clarify and extend term of agreement and to amend economic terms of agreement following a patent expiry in nov 2017.  Full Article

3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly
Tuesday, 16 May 2017 07:56am EDT 

May 16 (Reuters) - 3sbio Inc <1530.HK>:Enters distribution and promotion agreement with two subsidiaries of Eli Lilly and co for distribution and promotion of insulin products.Co has been granted exclusive right of distribution and promotion of Humulin, an insulin product of Lilly, in China from July 1, 2017.3Sbio will establish a marketing and promotion team which will cover a wide array of diabetes products, including Humulin.  Full Article

Lupin and Lilly expand partnership in India
Tuesday, 16 May 2017 06:22am EDT 

May 16 (Reuters) - Lupin Ltd :Says Lupin and Lilly expand partnership in India.Says Lilly will be responsible for manufacturing and importing the product.Says exclusive licensing agreement with Eli Lilly enables lupin to commercialize and distribute cialis.  Full Article

Soros Fund Management dissolves share stake in Ebay Inc
Monday, 15 May 2017 05:45pm EDT 

May 15 (Reuters) - Soros Fund Management ::Soros Fund Management dissolves share stake in eBay Inc.Soros Fund Management takes share stake of 3,900 shares in Eli Lilly & Co.Change in holdings are as of march 31, 2017 and compared with the previous quarter ended as of dec 31, 2016.  Full Article

Lilly announces positive results for three phase 3 studies of galcanezumab
Friday, 12 May 2017 06:45am EDT 

May 12 (Reuters) - Eli Lilly And Co : :Lilly announces positive results for three phase 3 studies of galcanezumab for the prevention of episodic and chronic migraine.Eli Lilly and Co - galcanezumab, an investigational treatment for prevention of episodic and chronic migraine, met its primary endpoint.Eli Lilly and Co - galcanezumab primary endpoint in three phase 3 studies (evolve-1, evolve-2 and regain).Eli Lilly and Co - also is evaluating galcanezumab for treatment of cluster headache, with phase 3 trial results expected in 2018.Eli Lilly and Co - patients treated with galcanezumab experienced statistically significant improvement versus placebo on several pre-specified secondary endpoints.Says it will submit a biologics license application to u.s. Food and drug administration (FDA) for galcanezumab in second half of 2017.Eli Lilly and Co - based on unmet medical need and significance of this disease for patients, lilly has been granted fast track designation from FDA.Says the BLA submission will be followed by submissions to other regulatory agencies around world.Eli Lilly and Co- in the three studies, most commonly-reported adverse events were injection site reactions, including pain.  Full Article

Eli Lilly and Co files for potential three-part notes offering
Thursday, 4 May 2017 08:42am EDT 

May 4 (Reuters) - Eli Lilly And Co : :Eli Lilly and Co files for potential three-part notes offering; size undisclosed .  Full Article

Incyte Q1 loss per share $0.96
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Incyte Corp :Incyte reports 2017 first-quarter financial results and updates on key clinical programs.Q1 revenue $384 million versus i/b/e/s view $360.1 million.Q1 loss per share $0.96.Q1 earnings per share view $-1.00 -- Thomson Reuters I/B/E/S.Incyte corp - Olumiant(®) (baricitinib) approved by european commission for treatment of moderate to severe active rheumatoid arthritis.Incyte corp - incyte and lilly disagree with fda's complete response letter for baricitinib.Incyte corp - expects that lilly will now engage with fda to discuss agency's concerns and determine a potential path forward.Incyte corp - novartis anticipates submitting an nda for capmatinib, incyte's potent and selective c-met inhibitor, in 2018.  Full Article

Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share
Monday, 1 May 2017 02:45pm EDT 

May 1 (Reuters) - Eli Lilly and Co ::Sets quarterly dividend of $0.52 per share.  Full Article

Eli Lilly says got civil investigative demand from Washington AG's office about pricing of insulin products
Monday, 1 May 2017 12:17pm EDT 

May 1 (Reuters) - Eli Lilly And Co :Lilly says got civil investigative demand from washington ag's office about pricing of insulin products, relationships with pharmacy benefit managers.Lilly says got civil investigative demand from state of new mexico's office of the attorney general relating to pricing of insulin products - sec filing.  Full Article

Lilly Q1 non-GAAP earnings per share $0.98
Tuesday, 25 Apr 2017 06:25am EDT 

April 25 (Reuters) - Eli Lilly And Co ::Lilly reports first-quarter 2017 results.Q1 revenue $5.228 billion versus I/B/E/S view $5.21 billion.Sees FY 2017 earnings per share $2.60 to $2.70.Q1 non-GAAP earnings per share $0.98.Q1 loss per share $0.10.Sees FY 2017 revenue $21.8 billion to $22.3 billion.Q1 earnings per share view $0.96 -- Thomson Reuters I/B/E/S.Eli Lilly And Co - qtrly Cymbalta sales $174.6 million versus $198.7 million.For Q1 of 2017, Alimta generated worldwide revenue of $489.9 million, which decreased 13 percent.Fy2017 earnings per share view $4.11, revenue view $22.11 billion -- Thomson Reuters I/B/E/S.Worldwide Jardiance revenue during q1 of 2017 was $74.0 million, an increase of 94 percent.Eli Lilly And Co - "Lilly's new product launches, including trulicity and taltz, led company to a strong quarter of volume-driven revenue growth".Eli Lilly And Co - in Q1 of 2017, company recognized an acquired in-process research and development charge of $857.6 million.On a non-GAAP basis, company has reaffirmed 2017 EPS to be in range of $4.05 to $4.15.Eli Lilly - recognized acquired in-process research and development charge of $857.6 million in quarter associated with acquisition of colucid pharmaceuticals.Eli Lilly and Co - in q1 of 2016, company recognized asset impairment, restructuring and other special charges of $131.4 million.Says in Q1 2017, recognized asset impairment, restructuring and other special charges of $213.9 million.  Full Article

More From Around the Web

CORRECTED-RPT-U.S., China accelerate beef talks; deal possible by early June

CHICAGO, May 19 Talks on restarting U.S. beef exports to China are moving fast and final details should be in place by early June, the U.S. Department of Agriculture said on Friday, allowing American farmers to vie for business that has been lost by rival Brazil.